1. High-dose chemotherapy with stem cell rescue as initial therapy for anaplastic oligodendroglioma: Long-term follow-up
- Author
-
Steven S. Rosenfeld, Lode J. Swinnen, Lisa M. DeAngelis, Donna Salzman, David A. Ramsay, Douglas A. Stewart, Susan A. Weaver, Stephen D. Nimer, Lauren E. Abrey, Jonathan L. Finlay, J. Gregory Cairncross, Anne Smith, David R. Macdonald, Sharon Gardner, Kendra Peterson, Nina Paleologos, L. Kaminer, Barrett H. Childs, Robert Bayer, Wendy W. Hu, and Peter A. Forsyth
- Subjects
Adult ,Male ,Cancer Research ,medicine.medical_specialty ,Autologous Stem Cell Rescue ,Adolescent ,medicine.medical_treatment ,Oligodendroglioma ,Clinical Investigations ,Antineoplastic Agents ,Hematopoietic stem cell transplantation ,ThioTEPA ,Procarbazine ,Disease-Free Survival ,Lomustine ,Antineoplastic Combined Chemotherapy Protocols ,medicine ,Humans ,Progression-free survival ,Aged ,Brain Neoplasms ,business.industry ,Hematopoietic Stem Cell Transplantation ,Middle Aged ,medicine.disease ,Combined Modality Therapy ,Survival Analysis ,Surgery ,Transplantation ,Treatment Outcome ,Oncology ,Vincristine ,Female ,Neurology (clinical) ,business ,Thiotepa ,Follow-Up Studies ,medicine.drug - Abstract
We previously reported a phase 2 trial of 69 patients with newly diagnosed anaplastic or aggressive oligodendroglioma who were treated with intensive procarbazine, CCNU (lomustine), and vincristine (PCV) followed by high-dose thiotepa with autologous stem cell rescue. This report summarizes the long-term follow-up of the cohort of 39 patients who received high-dose thiotepa with autologous stem cell support. Thirty-nine patients with a median age of 43 (range, 18–67) and a median KPS of 100 (range, 70–100) were treated. Surviving patients now have a median follow-up of 80.5 months (range, 44–142). The median progression-free survival is 78 months, and median overall survival has not been reached. Eighteen patients (46%) have relapsed. Neither histology nor prior low-grade oligodendroglioma correlated with risk of relapse. Persistent nonenhancing tumor at transplant was identified in our initial report as a significant risk factor for relapse; however, long-term follow-up has not confirmed this finding. Long-term neurotoxicity has developed only in those patients whose disease relapsed and required additional therapy; no patient in continuous remission has developed a delayed neurologic injury. This treatment strategy affords long-term disease control to a subset of patients with newly diagnosed anaplastic oligodendroglioma without evidence of delayed neurotoxicity or myelodysplasia.
- Published
- 2006